---
title: Investigating Rosuvastatin DDI Prediction
description: Read our poster. E3S as a Surrogate BCRP In Vitro Probe Substrate for Rosuvastatin DDI Prediction. Contact Evotec to learn more!
image: https://news.cyprotex.com/hubfs/Sciencepool/Sciencepool%20images/Shutterstock%20images/shutterstock_718685998-transporters-blue-01-science-pool.jpg
---

[![Cyprotex | The Leading ADME-Tox Specialist](https://news.cyprotex.com/hs-fs/hubfs/cyprotex%20logo.png?width=224&height=62&name=cyprotex%20logo.png "Cyprotex | The Leading ADME-Tox Specialist")](https://www.cyprotex.com/)

# Science Pool

# Investigating Rosuvastatin DDI Prediction

Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 11, 2021 7:55:59 PM

Rosuvastatin is used in the treatment of dyslipidemia. The drug transporter BCRP (breast cancer resistant protein) has been identified as the rate limiting barrier to rosuvastatin absorption.

In this poster, we focus on:

- whether estrone 3-sulfate can be applied as a surrogate *in vitro* BCRP probe substrate for predicting rosuvastatin DDI 
- a comparison of BCRP inhibition assessment using rosuvastatin or estrone 3-sulfate as probe substrate for six established BCRP inhibitors for which a clinical DDI with rosuvastatin has been characterised

Read our poster to learn more about our research!

[LEARN MORE](https://news.cyprotex.com/hubfs/Sciencepool/Posters/Cyprotex%20posters/e3s-bcrp-substrate-ddi-prediction-7thiccrdt2016.pdf)

 

 

 

 Tags: [Posters](https://news.cyprotex.com/sciencepool/tag/posters), [ADME/DMPK](https://news.cyprotex.com/sciencepool/tag/adme-dmpk)